{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:36:10Z","timestamp":1793093770734,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Erste akute Episoden oder schwerwiegende rezidivierende Verl\u00e4ufe einer Schizophrenie treten h\u00e4ufig im Transitionsalter auf\u00a0\u2013 dem \u00dcbergang zwischen den kinder- und jugendpsychiatrischen sowie den erwachsenenpsychiatrischen Versorgungssystemen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel der Arbeit<\/jats:title>\n                    <jats:p>Erarbeitung von Herausforderungen und Empfehlungen f\u00fcr die Transition von Patientinnen und Patienten mit Schizophrenie.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methode<\/jats:title>\n                    <jats:p>Es wurde ein narrativer Review durchgef\u00fchrt unter Einbezug der aktuellen S3-Leitlinie Schizophrenie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Die leitliniengerechte Fr\u00fcherkennung und Behandlung der Schizophrenie stellt bereits unabh\u00e4ngig von der Transition eine Herausforderung dar. Empfehlungen zur Transition betreffen f\u00fcr Kliniken und Niedergelassene Elemente der Erkrankung selbst, der Versorgungs- und Weiterbildungsstruktur und -kultur sowie der Gestaltung und Finanzierung von Behandlungs\u00fcberg\u00e4ngen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>Die aktualisierte 2025 publizierte S3-Leitlinie Schizophrenie enth\u00e4lt zahlreiche Empfehlungen f\u00fcr eine koordinierte Behandlung in der Transitionsphase, h\u00e4lt jedoch in gro\u00dfen Teilen an der Altersgrenze von 18\u00a0Jahren fest. F\u00fcr eine optimale Versorgung im Transitionsalter sind spezialisierte Fr\u00fcherkennungs- und Fr\u00fchinterventionszentren erforderlich. Eine bidirektionale Flexibilisierung der Altersgrenze zwischen den Versorgungssystemen sowie eine \u00fcberlappende Behandlung in der Transitionsphase erscheinen in bestimmten F\u00e4llen sinnvoll.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00115-025-01936-1","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:26:24Z","timestamp":1768911984000},"page":"223-231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transition: Herausforderungen und Empfehlungen f\u00fcr Jugendliche und junge Erwachsene mit Schizophrenie","Transition: challenges and recommendations for adolescents and young adults with schizophrenia"],"prefix":"10.1007","volume":"97","author":[{"given":"Benno Graf","family":"Schimmelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkomiet","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"1936_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.euroneuro.2022.04.005","volume":"59","author":"C Arango","year":"2022","unstructured":"Arango\u00a0C, Buitelaar\u00a0JK, Correll\u00a0CU et\u00a0al (2022) The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. Eur Neuropsychopharmacol 59:45\u201355","journal-title":"Eur Neuropsychopharmacol"},{"key":"1936_CR2","unstructured":"Awmf (2025) S3-Leitlinie Schizophrenie (living). In: Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie PuN (ed). https:\/\/register.awmf.org\/de\/leitlinien\/detail\/038-009"},{"key":"1936_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/21642850.2014.927738","volume":"2","author":"J Bartlett","year":"2014","unstructured":"Bartlett\u00a0J (2014) Childhood-onset schizophrenia: what do we really know? Health Psychol Behav Med 2:735\u2013747","journal-title":"Health Psychol Behav Med"},{"key":"1936_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1192\/bjp.bp.114.160630","volume":"207","author":"DJ Castle","year":"2015","unstructured":"Castle\u00a0DJ, Singh\u00a0SP (2015) Early intervention in psychosis: still the \u2018best buy\u2019? Br J Psychiatry 207:288\u2013292","journal-title":"Br J Psychiatry"},{"key":"1936_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamapsychiatry.2018.0623","volume":"75","author":"CU Correll","year":"2018","unstructured":"Correll\u00a0CU, Galling\u00a0B, Pawar\u00a0A et\u00a0al (2018) Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A\u00a0Systematic Review, Meta-analysis, and Meta-regression. Jama Psychiatry 75:555\u2013565","journal-title":"JAMA Psychiatry"},{"key":"1936_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1024\/1422-4917\/a000502","volume":"45","author":"JM Fegert","year":"2017","unstructured":"Fegert\u00a0JM, Hauth\u00a0I, Banaschewski\u00a0T et\u00a0al (2017) Z\u00a0Kinder Jugendpsychiatr Psychother 45:80\u201385. https:\/\/doi.org\/10.1024\/1422-4917\/a000502","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"key":"1936_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/cap.2005.15.497","volume":"15","author":"SA Hlastala","year":"2005","unstructured":"Hlastala\u00a0SA, Mcclellan\u00a0J (2005) Phenomenology and diagnostic stability of youths with atypical psychotic symptoms. J\u00a0Child Adolesc Psychopharmacol 15:497\u2013509","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1936_CR8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/a-1025-1994","volume":"87","author":"A Karow","year":"2019","unstructured":"Karow\u00a0A, Holtmann\u00a0M, Koutsouleris\u00a0N et\u00a0al (2019) Psychotic disorders in the transition phase: early detection and early intervention. Fortschr Neurol Psychiatr 87:629\u2013633","journal-title":"Fortschr Neurol Psychiatr"},{"key":"1936_CR9","doi-asserted-by":"publisher","first-page":"116007","DOI":"10.1016\/j.psychres.2024.116007","volume":"339","author":"M Lambert","year":"2024","unstructured":"Lambert\u00a0M, Konig\u00a0H, Karow\u00a0A et\u00a0al (2024) Stepped, evidence-based and integrated care service model vs. usual care for mental disorders: A\u00a0randomized controlled trial (RECOVER). Psychiatry Res 339:116007","journal-title":"Psychiatry Res"},{"key":"1936_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J Mcgrath","year":"2008","unstructured":"Mcgrath\u00a0J, Saha\u00a0S, Chant\u00a0D et\u00a0al (2008) Schizophrenia: a\u00a0concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67\u201376","journal-title":"Epidemiol Rev"},{"key":"1936_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00115-019-00836-5","volume":"91","author":"E Meisenzahl","year":"2020","unstructured":"Meisenzahl\u00a0E, Walger\u00a0P, Schmidt\u00a0SJ et\u00a0al (2020) Early recognition and prevention of schizophrenia and other psychoses. Nervenarzt 91:10\u201317","journal-title":"Nervenarzt"},{"key":"1936_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaac.2016.12.013","volume":"56","author":"AK Pagsberg","year":"2017","unstructured":"Pagsberg\u00a0AK, Tarp\u00a0S, Glintborg\u00a0D et\u00a0al (2017) Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A\u00a0Systematic Review and Network Meta-Analysis. J\u00a0Am Acad Child Adolesc Psychiatry 56:191\u2013202","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1936_CR13","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","volume":"2","author":"S Saha","year":"2005","unstructured":"Saha\u00a0S, Chant\u00a0D, Welham\u00a0J et\u00a0al (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2:e141","journal-title":"PLoS Med"},{"key":"1936_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eurpsy.2015.01.010","volume":"30","author":"F Schultze-Lutter","year":"2015","unstructured":"Schultze-Lutter\u00a0F, Michel\u00a0C, Schmidt\u00a0SJ et\u00a0al (2015) EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry 30:405\u2013416","journal-title":"Eur Psychiatry"},{"key":"1936_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/acps.12082","volume":"128","author":"E Shorter","year":"2013","unstructured":"Shorter\u00a0E, Wachtel\u00a0LE (2013) Childhood catatonia, autism and psychosis past and present: is there an \u2018iron triangle\u2019? Acta Psychiatr Scand 128:21\u201333","journal-title":"Acta Psychiatr Scand"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-025-01936-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-025-01936-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-025-01936-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:04:57Z","timestamp":1793091897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-025-01936-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1936"],"URL":"https:\/\/doi.org\/10.1007\/s00115-025-01936-1","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.G. Schimmelmann erhielt Vortragshonorare von Medice und Takeda und Beraterhonorare von AGB Pharma und Axunio Pharma. A. Hasan ist federf\u00fchrende Autor der S3-Leitlinie Schizophrenie (Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, DGPPN) und Erstautor der WFSBP(World Federation of Societies of Biological Psychiatry)-Leitlinien Guidelines for Biological Treatment of Schizophrenia. Dar\u00fcber hinaus war er Mitglied in Beir\u00e4ten und erhielt Vortragshonorare: AbbVie (nur Vortragshonorare), Advanz (nur Vortragshonorare), Janssen-Cilag, Lundbeck, Recordati, Rovi und Otsuka (beides), Teva und Axunio (Beratert\u00e4tigkeit).","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}